Dr. Pablo Andres Altschwager Kreft is a Boston, Massachusetts based male Ophthalmologist who is specialized in Ophthalmology. Active license number of Dr. Pablo Andres Altschwager Kreft is 292586 for Ophthalmology in Massachusetts. Dr. Pablo Andres Altschwager Kreft is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Dr. Pablo Andres Altschwager Kreft speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1023425832
NPI Enumeration Date:
14 Jul, 2014
NPI Last Update On:
28 Jul, 2022
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Pablo Andres Altschwager Kreft are as mentioned below.
License Number
Specialization
State
Status
292586
Ophthalmology
Massachusetts
Primary
259334
Ophthalmology
Massachusetts
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
300 Longwood Ave, Fegan 4. Boston, Massachusetts
Zip:
02115-5724
Phone Number:
617-355-8761
Fax Number:
617-531-1844
Patients can reach Dr. Pablo Andres Altschwager Kreft at 300 Longwood Ave, Fegan 4, Boston, Massachusetts or can call to book an appointment on 617-355-8761. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 October, 2024.